Figure 6 | British Journal of Cancer

Figure 6

From: Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells

Figure 6

Western blot analysis on expression levels of CDKIs p21 and p27 in KPL-3C (A) and MDA-MB-231 (B) cells. Semi-confluent cells were cultured for 2 days in the oestrogen-deprived medium with vehicle (control), 1 nM E2, 1 nM E2 plus 100 nM fulvestrant, 1 nM E2 plus 10 μ M gefitinib, 1 nM E2 plus 100 nM fulvestrant and 10 μ M gefitinib or 10 μ M gefitinib alone. The harvested cells were lysed, and the lysate was subjected to electrophoresis on polyacrylamide gel. The protein was transferred to nitrocellulose membranes and immunoblotted with appropriate primary antibodies. For detection, the blots were incubated with the appropriate secondary antibodies conjugated with horseradish peroxidase, and developed using ECL Plus Western Blotting Detection Reagents. Actin or α-tubulin was used as the internal control.

Back to article page